These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 8523125

  • 1. In vitro and in vivo evaluation of copper-64-octreotide conjugates.
    Anderson CJ, Pajeau TS, Edwards WB, Sherman EL, Rogers BE, Welch MJ.
    J Nucl Med; 1995 Dec; 36(12):2315-25. PubMed ID: 8523125
    [Abstract] [Full Text] [Related]

  • 2. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
    Breeman WA, Hofland LJ, van der Pluijm M, van Koetsveld PM, de Jong M, Setyono-Han B, Bakker WH, Kwekkeboom DJ, Visser TJ, Lamberts SW.
    Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
    [Abstract] [Full Text] [Related]

  • 3. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
    Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, Lewis JS, McCarthy DW.
    J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
    [Abstract] [Full Text] [Related]

  • 4. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.
    Bakker WH, Albert R, Bruns C, Breeman WA, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B, Koper JW.
    Life Sci; 1991 Feb; 49(22):1583-91. PubMed ID: 1658515
    [Abstract] [Full Text] [Related]

  • 5. Generally applicable, convenient solid-phase synthesis and receptor affinities of octreotide analogs.
    Edwards WB, Fields CG, Anderson CJ, Pajeau TS, Welch MJ, Fields GB.
    J Med Chem; 1994 Oct 28; 37(22):3749-57. PubMed ID: 7966134
    [Abstract] [Full Text] [Related]

  • 6. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M, Béhé M, Guhlke S, Otte R, Bender H, Maecke HR, Biersack HJ.
    Eur J Nucl Med; 2000 Jun 28; 27(6):628-37. PubMed ID: 10901448
    [Abstract] [Full Text] [Related]

  • 7. In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats.
    Bakker WH, Krenning EP, Reubi JC, Breeman WA, Setyono-Han B, de Jong M, Kooij PP, Bruns C, van Hagen PM, Marbach P.
    Life Sci; 1991 Jun 28; 49(22):1593-601. PubMed ID: 1658516
    [Abstract] [Full Text] [Related]

  • 8. Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy.
    Lewis JS, Lewis MR, Srinivasan A, Schmidt MA, Wang J, Anderson CJ.
    J Med Chem; 1999 Apr 22; 42(8):1341-7. PubMed ID: 10212119
    [Abstract] [Full Text] [Related]

  • 9. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
    Hofland LJ, Lamberts SW, van Hagen PM, Reubi JC, Schaeffer J, Waaijers M, van Koetsveld PM, Srinivasan A, Krenning EP, Breeman WA.
    J Nucl Med; 2003 Aug 22; 44(8):1315-21. PubMed ID: 12902423
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector.
    Rogers BE, McLean SF, Kirkman RL, Della Manna D, Bright SJ, Olsen CC, Myracle AD, Mayo MS, Curiel DT, Buchsbaum DJ.
    Clin Cancer Res; 1999 Feb 22; 5(2):383-93. PubMed ID: 10037188
    [Abstract] [Full Text] [Related]

  • 12. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide.
    Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ.
    J Nucl Med; 2000 Jun 22; 41(6):1114-9. PubMed ID: 10855644
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D, Béhé M, Walter MA, Chen J, Powell P, Mikolajczak R, Mäcke HR.
    J Nucl Med; 2005 Sep 22; 46(9):1561-9. PubMed ID: 16157541
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours.
    Smith-Jones PM, Stolz B, Albert R, Ruser G, Briner U, Mäcke HR, Bruns C.
    Nucl Med Biol; 1998 Apr 22; 25(3):181-8. PubMed ID: 9620621
    [Abstract] [Full Text] [Related]

  • 15. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
    Janson ET, Westlin JE, Ohrvall U, Oberg K, Lukinius A.
    J Nucl Med; 2000 Sep 22; 41(9):1514-8. PubMed ID: 10994731
    [Abstract] [Full Text] [Related]

  • 16. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator.
    Sprague JE, Peng Y, Sun X, Weisman GR, Wong EH, Achilefu S, Anderson CJ.
    Clin Cancer Res; 2004 Dec 15; 10(24):8674-82. PubMed ID: 15623652
    [Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake.
    Lewis JS, Srinivasan A, Schmidt MA, Anderson CJ.
    Nucl Med Biol; 1999 Apr 15; 26(3):267-73. PubMed ID: 10363797
    [Abstract] [Full Text] [Related]

  • 18. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats.
    Anderson CJ, Jones LA, Bass LA, Sherman EL, McCarthy DW, Cutler PD, Lanahan MV, Cristel ME, Lewis JS, Schwarz SW.
    J Nucl Med; 1998 Nov 15; 39(11):1944-51. PubMed ID: 9829587
    [Abstract] [Full Text] [Related]

  • 19. Distribution and elimination characteristics of 111In-DTPA-D-phe1-octreotide and 111In-DTPA-L-phe1-octreotide in rats.
    Laznickova A, Laznicek M, Trejtnar F, Melicharova L, Suzuki KH, Akizawa H, Arano Y, Yokoyama A.
    Eur J Drug Metab Pharmacokinet; 2002 Nov 15; 27(1):37-43. PubMed ID: 11996325
    [Abstract] [Full Text] [Related]

  • 20. Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo.
    Akizawa H, Arano Y, Uezono T, Ono M, Fujioka Y, Uehara T, Yokoyama A, Akaji K, Kiso Y, Koizumi M, Saji H.
    Bioconjug Chem; 1998 Nov 15; 9(6):662-70. PubMed ID: 9815158
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.